Streetbeat News

Price Targets

ADBE

Adobe (NASDAQ:ADBE) received mixed ratings from 15 analysts in the past three months, with an average 12-month price target of $658.33, up 5.82% from the previous target. Analysts from firms like Piper Sandler, Barclays, and Citigroup have raised their price targets, reflecting a positive outlook on Adobe's performance. Adobe's financial indicators such as revenue growth, net margin, ROE, ROA, and debt management are strong compared to industry averages.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

CFLT

Confluent Inc (NASDAQ:CFLT) has received mixed analyst ratings over the past three months, with 17 analysts offering diverse perspectives. The average 12-month price target is $26.71, a significant decrease from the previous $38.56. Analysts have adjusted their ratings and price targets, with some raising and others lowering their expectations. Confluent's financials show a revenue growth rate of 31.93% as of September 30, 2023, but it struggles with a net margin of -46.29%, an ROE of -11.95%, an ROA of -3.95%, and a high debt-to-equity ratio of 1.41.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

AVY

Avery Dennison (NYSE:AVY) received mixed analyst ratings over the past three months, with 3 bullish and 1 underperform rating. The 12-month price target average for AVY is $209.00, slightly down from the previous $210.00. Analysts from B of A Securities, Truist Securities, and Citigroup have provided recent evaluations, with price target adjustments reflecting their latest views on the company's performance. Avery Dennison's financials show a revenue decline of -9.44% over the past 3 months, but strong profitability with a net margin of 6.59% and ROE of 6.78%. The company's international operations contribute significantly to its sales, and it maintains a balanced debt approach with a debt-to-equity ratio of 1.61.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

GDRX

GoodRx Holdings (NASDAQ:GDRX) has been the subject of diverse analyst opinions over the past three months, with 7 analysts providing ratings. The consensus over the last 30 days has shifted to a more bearish stance, with 6 indifferent and 1 somewhat bearish rating. The average 12-month price target is now $5.5, down from the previous $7.57, indicating a negative sentiment. Analysts from firms including B of A Securities, JP Morgan, Goldman Sachs, RBC Capital, Truist Securities, and Morgan Stanley have all lowered their price targets for GDRX, reflecting concerns over its market performance and financials. Despite a strong market capitalization and net margin, GoodRx Holdings has seen a revenue decline of -3.93% and has a negative ROE and ROA.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 4:00 pm

PCVX

B of A Securities analyst Jason Gerberry has maintained a Buy rating on Vaxcyte (NASDAQ:PCVX) and increased the price target from $67 to $80. This adjustment reflects a positive outlook on the company's stock, suggesting potential upside from its current trading level.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 3:58 pm

ROIV

B of A Securities analyst Chi Fong has maintained a Neutral rating on Roivant Sciences (NASDAQ:ROIV) and increased the price target from $11 to $12.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 3:55 pm

MLCO

Morgan Stanley analyst Praveen Choudhary has downgraded Melco Resorts and Entertainment (MLCO) from Overweight to Equal-Weight and set a price target of $9.6.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 3:48 pm

XENE

B of A Securities analyst Jason Gerberry has maintained a Buy rating on Xenon Pharmaceuticals (NASDAQ:XENE) and increased the price target from $52 to $56.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 3:48 pm

ATAI

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on ATAI Life Sciences (NASDAQ:ATAI) and maintained a $20 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 3:41 pm

AAPL

Apple Inc (AAPL) stock is down after Barclays analyst Tim Long downgraded the stock from Equal-Weight to Underweight and lowered the price target from $161 to $160. Long cites weakness in iPhone volumes and mix, lack of recovery in Macs, iPads, and wearables, and worse IP15 data from China. He expects a largely in-line December quarter but has reduced his March quarter estimates below consensus, anticipating a year-over-year revenue decline after a flat December quarter. Long also sees service risks emerging in 2024 and believes the current multiple expansions are unsustainable.

Portfolio Pulse from Anusuya Lahiri

January 02, 2024 | 3:40 pm